290 related articles for article (PubMed ID: 33510281)
1. Identification of triptonide as a therapeutic agent for triple negative breast cancer treatment.
Gao B; Chen J; Han B; Zhang X; Hao J; Giuliano AE; Cui Y; Cui X
Sci Rep; 2021 Jan; 11(1):2408. PubMed ID: 33510281
[TBL] [Abstract][Full Text] [Related]
2. Triptonide effectively inhibits triple-negative breast cancer metastasis through concurrent degradation of Twist1 and Notch1 oncoproteins.
Zhang M; Meng M; Liu Y; Qi J; Zhao Z; Qiao Y; Hu Y; Lu W; Zhou Z; Xu P; Zhou Q
Breast Cancer Res; 2021 Dec; 23(1):116. PubMed ID: 34922602
[TBL] [Abstract][Full Text] [Related]
3. Targeting of multiple senescence-promoting genes and signaling pathways by triptonide induces complete senescence of acute myeloid leukemia cells.
Pan Y; Meng M; Zheng N; Cao Z; Yang P; Xi X; Zhou Q
Biochem Pharmacol; 2017 Feb; 126():34-50. PubMed ID: 27908660
[TBL] [Abstract][Full Text] [Related]
4. Triptonide acts as a novel potent anti-lymphoma agent with low toxicity mainly through inhibition of proto-oncogene Lyn transcription and suppression of Lyn signal pathway.
Yang P; Dong F; Zhou Q
Toxicol Lett; 2017 Aug; 278():9-17. PubMed ID: 28666825
[TBL] [Abstract][Full Text] [Related]
5. Triptonide inhibits lung cancer cell tumorigenicity by selectively attenuating the Shh-Gli1 signaling pathway.
Zhang M; Tan S; Yu D; Zhao Z; Zhang B; Zhang P; Lv C; Zhou Q; Cao Z
Toxicol Appl Pharmacol; 2019 Feb; 365():1-8. PubMed ID: 30610878
[TBL] [Abstract][Full Text] [Related]
6. A new oridonin analog suppresses triple-negative breast cancer cells and tumor growth via the induction of death receptor 5.
Wu J; Ding Y; Chen CH; Zhou Z; Ding C; Chen H; Zhou J; Chen C
Cancer Lett; 2016 Oct; 380(2):393-402. PubMed ID: 27387452
[TBL] [Abstract][Full Text] [Related]
7. Triptonide effectively suppresses gastric tumor growth and metastasis through inhibition of the oncogenic Notch1 and NF-κB signaling pathways.
Xiang S; Zhao Z; Zhang T; Zhang B; Meng M; Cao Z; Zhou Q
Toxicol Appl Pharmacol; 2020 Feb; 388():114870. PubMed ID: 31866380
[TBL] [Abstract][Full Text] [Related]
8. NOTCH4 maintains quiescent mesenchymal-like breast cancer stem cells via transcriptionally activating SLUG and GAS1 in triple-negative breast cancer.
Zhou L; Wang D; Sheng D; Xu J; Chen W; Qin Y; Du R; Yang X; He X; Xie N; Liu S; Zhang L
Theranostics; 2020; 10(5):2405-2421. PubMed ID: 32104513
[No Abstract] [Full Text] [Related]
9. BRCA1-IRIS inactivation overcomes paclitaxel resistance in triple negative breast cancers.
Blanchard Z; Paul BT; Craft B; ElShamy WM
Breast Cancer Res; 2015 Jan; 17(1):5. PubMed ID: 25583261
[TBL] [Abstract][Full Text] [Related]
10. Targeting breast cancer stem cells in triple-negative breast cancer using a combination of LBH589 and salinomycin.
Kai M; Kanaya N; Wu SV; Mendez C; Nguyen D; Luu T; Chen S
Breast Cancer Res Treat; 2015 Jun; 151(2):281-94. PubMed ID: 25904215
[TBL] [Abstract][Full Text] [Related]
11. EP300 knockdown reduces cancer stem cell phenotype, tumor growth and metastasis in triple negative breast cancer.
Ring A; Kaur P; Lang JE
BMC Cancer; 2020 Nov; 20(1):1076. PubMed ID: 33167919
[TBL] [Abstract][Full Text] [Related]
12. Anti-cell growth and anti-cancer stem cell activities of the non-canonical hedgehog inhibitor GANT61 in triple-negative breast cancer cells.
Koike Y; Ohta Y; Saitoh W; Yamashita T; Kanomata N; Moriya T; Kurebayashi J
Breast Cancer; 2017 Sep; 24(5):683-693. PubMed ID: 28144905
[TBL] [Abstract][Full Text] [Related]
13. Dual Inhibition of Key Proliferation Signaling Pathways in Triple-Negative Breast Cancer Cells by a Novel Derivative of Taiwanin A.
Kuo YH; Chiang EI; Chao CY; Rodriguez RL; Chou PY; Tsai SY; Pai MH; Tang FY
Mol Cancer Ther; 2017 Mar; 16(3):480-493. PubMed ID: 27956520
[TBL] [Abstract][Full Text] [Related]
14. Suppressive role exerted by microRNA-29b-1-5p in triple negative breast cancer through SPIN1 regulation.
Drago-Ferrante R; Pentimalli F; Carlisi D; De Blasio A; Saliba C; Baldacchino S; Degaetano J; Debono J; Caruana-Dingli G; Grech G; Scerri C; Tesoriere G; Giordano A; Vento R; Di Fiore R
Oncotarget; 2017 Apr; 8(17):28939-28958. PubMed ID: 28423652
[TBL] [Abstract][Full Text] [Related]
15. Drug resistance profiling of a new triple negative breast cancer patient-derived xenograft model.
Matossian MD; Burks HE; Elliott S; Hoang VT; Bowles AC; Sabol RA; Wahba B; Anbalagan M; Rowan B; Abazeed ME; Bunnell BA; Moroz K; Miele L; Rhodes LV; Jones SD; Martin EC; Collins-Burow BM; Burow ME
BMC Cancer; 2019 Mar; 19(1):205. PubMed ID: 30845999
[TBL] [Abstract][Full Text] [Related]
16. Signaling pathway inhibitors target breast cancer stem cells in triple-negative breast cancer.
Li W; Yang H; Li X; Han L; Xu N; Shi A
Oncol Rep; 2019 Jan; 41(1):437-446. PubMed ID: 30365081
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of iNOS as a novel effective targeted therapy against triple-negative breast cancer.
Granados-Principal S; Liu Y; Guevara ML; Blanco E; Choi DS; Qian W; Patel T; Rodriguez AA; Cusimano J; Weiss HL; Zhao H; Landis MD; Dave B; Gross SS; Chang JC
Breast Cancer Res; 2015 Feb; 17(1):25. PubMed ID: 25849745
[TBL] [Abstract][Full Text] [Related]
18. Discovery of a natural small-molecule compound that suppresses tumor EMT, stemness and metastasis by inhibiting TGFβ/BMP signaling in triple-negative breast cancer.
Di L; Liu LJ; Yan YM; Fu R; Li Y; Xu Y; Cheng YX; Wu ZQ
J Exp Clin Cancer Res; 2019 Mar; 38(1):134. PubMed ID: 30898152
[TBL] [Abstract][Full Text] [Related]
19. Sulforaphane Suppresses the Growth of Triple-negative Breast Cancer Stem-like Cells
Castro NP; Rangel MC; Merchant AS; MacKinnon G; Cuttitta F; Salomon DS; Kim YS
Cancer Prev Res (Phila); 2019 Mar; 12(3):147-158. PubMed ID: 30679159
[TBL] [Abstract][Full Text] [Related]
20. The opposing effects of interferon-beta and oncostatin-M as regulators of cancer stem cell plasticity in triple-negative breast cancer.
Doherty MR; Parvani JG; Tamagno I; Junk DJ; Bryson BL; Cheon HJ; Stark GR; Jackson MW
Breast Cancer Res; 2019 Apr; 21(1):54. PubMed ID: 31036052
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
